Ahluwalia, M. S., Papadantonakis, N., Alva Venur, V., Schilero, C., Peereboom, D. M., Stevens, G., … McCrae, K. (2015). Phase II trial of dovitinib in recurrent glioblastoma. In Journal of Clinical Oncology (Vol. 33, pp. 2050–2050). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.2050

Ahluwalia, Manmeet Singh, Nikolaos Papadantonakis, Vyshak Alva Venur, Cathy Schilero, David M. Peereboom, Glen Stevens, Steven Rosenfeld, et al. “Phase II trial of dovitinib in recurrent glioblastoma.” In Journal of Clinical Oncology, 33:2050–2050. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2050.

Ahluwalia MS, Papadantonakis N, Alva Venur V, Schilero C, Peereboom DM, Stevens G, et al. Phase II trial of dovitinib in recurrent glioblastoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2050–2050.

Ahluwalia, Manmeet Singh, et al. “Phase II trial of dovitinib in recurrent glioblastoma.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 2050–2050. Crossref, doi:10.1200/jco.2015.33.15_suppl.2050.

Ahluwalia MS, Papadantonakis N, Alva Venur V, Schilero C, Peereboom DM, Stevens G, Rosenfeld S, Vogelbaum MA, Elson P, Nixon AB, McCrae K. Phase II trial of dovitinib in recurrent glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2050–2050.